Key economic readings and Moderna’s vaccine had an impact on the global markets-Tuesday Review, November 17

By: Miguel A. Rodriguez

11:23, 18 November 2020

Once again, COVID-19 takes over the markets.

The US

The retail sales came in lower-than-expected, showing weakness in the US consumer, causing the benchmarks to close in the red. USA30 lost 0.56%, while USA500 was down 0.43%. TECH100 inched down 0.21%.

Crude oil slipped 0.3%, settling at $41.27 per barrel.

Gold added 0.1% to $1,888.90 per ounce.


Asia and Australia

The markets traded mixedly, being boosted by the news regarding Moderna's potential COVID-19 drug. On the other hand, tighter restrictions were announced to curb the infection.

Japan225 gained 0.42%, reaching a 29-year high.

HongKong45 lost 0.01%.

Down under, Australia200 added 0.33%.



The benchmarks drifted lower amid the rising COVID-19 infections even though many European countries have entered lockdowns. Germany30 went down 0.1%, while France40 closed 0.2% lower. UK100 dropped 0.3%.

Brent oil lost 0.1% and traded at $43.81 per barrel.

EUR/USD closed at 1.1870 after gaining 0.1%.


Share this article

This information prepared by is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation, or the particular needs of any recipient.You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation, or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.This information may not be published, circulated, reproduced, or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of Financial Services (Pty) Ltd trading as CAPEX.COM/ZA acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via CAPEX.COM/ZA, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15.  Magnasale Trading Ltd is the principal to the CFD purchased by investors.